Pacific Shuanglin Bio-pharmacy Co., Ltd.(000403.SZ)
No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 1,050 | 1,972 | 2,405 | 2,329 | 2,655 | 2,633 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 186 | 391 | 587 | 612 | 745 | 419 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Based in Taiyuan, China, Pacific Shuanglin Bio-pharmacy Co., Ltd. operates extensively within the country, focusing on biochemical engineering, the production of pharmaceutical industry equipment, and medical materials. The company's diverse product portfolio includes a range of vital human blood-derived therapies such as serum albumin, various forms of human immunoglobulin (including specific preparations for rabies, hepatitis B, tetanus, and intravenous human immunoglobulin (PH4)). They also manufacture topical remedies like tianqi analgesic cream, musk herd cream, musk bone paste, anti-inflammatory analgesic cream, and dieshangling plasters, alongside general medical gauzes. Beyond current offerings, Pacific Shuanglin is actively engaged in developing advanced biopharmaceutical products, including porcine pulmonary surfactants, shaqifang compounds, a1-protease inhibitors, human coagulation factor VIII products, and human fibrinogens. Furthermore, the company expands its interests to encompass investment, consultation, and technology promotion for pharmaceutical and biotechnology projects. Its broader ventures include real estate development, electronic product information services, and the provision of electricity. The entity adopted its current name, Pacific Shuanglin Bio-pharmacy Co., Ltd., in April 2021, having previously been known as Southern Shuanglin Bio-pharmacy Co., Ltd.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Pacific Shuanglin Bio-pharmacy Co., Ltd. (000403.SZ)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Based in Taiyuan, China, Pacific Shuanglin Bio-pharmacy Co., Ltd. operates extensively within the country, focusing on biochemical engineering, the production of pharmaceutical industry equipment, and medical materials. The company's diverse product portfolio includes a range of vital human blood-derived therapies such as serum albumin, various forms of human immunoglobulin (including specific preparations for rabies, hepatitis B, tetanus, and intravenous human immunoglobulin (PH4)). They also manufacture topical remedies like tianqi analgesic cream, musk herd cream, musk bone paste, anti-inflammatory analgesic cream, and dieshangling plasters, alongside general medical gauzes. Beyond current offerings, Pacific Shuanglin is actively engaged in developing advanced biopharmaceutical products, including porcine pulmonary surfactants, shaqifang compounds, a1-protease inhibitors, human coagulation factor VIII products, and human fibrinogens. Furthermore, the company expands its interests to encompass investment, consultation, and technology promotion for pharmaceutical and biotechnology projects. Its broader ventures include real estate development, electronic product information services, and the provision of electricity. The entity adopted its current name, Pacific Shuanglin Bio-pharmacy Co., Ltd., in April 2021, having previously been known as Southern Shuanglin Bio-pharmacy Co., Ltd.